ADVOCATE Frequently Asked Questions (FAQs)

An entity, under a single Unique Entity Identifier (UEI), can submit a single proposal as the prime proposer for TA1 or TA2 or TA3. Entities wishing to submit to both TA1 and TA2, must submit separate, technically independent proposals. Those interested in TA3 cannot submit a proposal for TA1 or TA2. Entities may propose within multiple teams as sub-proposers or other appropriate teaming arrangements.

Teaming profiles can be found on the ADVOCATE teaming page.

Refer to Section 2.1.3 of the ADVOCATE ISO regarding non-US entities.

No. This solicitation is open to all eligible proposers, and there is no consortia membership associated with this ISO.

To access the technical expertise drop down, a program needs to be selected first.

Having sub-proposers or being part of a multi-party team is not a requirement. Teams should create the strongest submission possible.Proposer team structure is not prescribed in the ISO. Consistent with Section 2.3 of the ISO, Proposer Team Structure, offerors should identify the teaming arrangement most suitable to their specific combination of expertise, capabilities, and execution plan.

Email advocate@arpa-h.gov. Include “Teaming Profile Update” in the subject.

No, a Principal Investigator can only submit one Solution Summary per TA.

• Under a prime/sub teaming arrangement, the prime’s authorized official/authorized organization representative is responsible for submitting the proposal on behalf of the entity.
• Multi-party teaming arrangements, the selected lead team member is responsible for submitting the proposal on behalf of the multi-party team.

See Section 3, Submission Information, and Appendix B, Solution Summary Format Instructions, of the ISO.

See ISO Section 5.1, “Proposers interested in submitting a proposal for TA3 cannot submit a proposal for TA1 and TA2 in any capacity (e.g. prime, subperformer, or multi-party team). TA3 proposers can only submit one proposal for the TA3 work outlined in this solicitation.”

Proposers interested in submitting a proposal for TA3 cannot submit a proposal for TA1 and TA2 in any capacity (e.g. prime, subperformer, or multi-party team). TA3 proposers can only submit one proposal for the TA3 work outlined in this solicitation.

If their health systems are proposing for TA3, clinicians can still be part of TA1/TA2 teams as independent consultants. Because conflict of interest mitigation between all proposers will be a key aspect of the program, conflicts of interest must be identified and disclosed in accordance with section 6.2 of the ADVOCATE ISO which may also require submission of a mitigation plan.

Proposers should propose costs that align with their proposed solution.

Yes, the ADVOCATE Proposers’ Day was recorded and is available on the ADVOCATE webpage under the heading Proposers' Day

ISO Section 1.2.2’s overview states that “TA1 and TA2 performers are encouraged to propose the use of industry standards for interoperability and orchestration.” Propose your recommended solution for interoperability and orchestration (data models, APIs, agent orchestration tools, etc.) that would enable a TA1 and TA2 solution to successfully work together.

ISO Section 1.2.2 states that “the target population will be individuals who are post-myocardial infarction or have heart failure.” A patient experiencing hypertension would need that managed, but looking at full chronic care management for HF and PMI patients.

ISO Section 1.2 states “Ensuring safety is paramount. ADVOCATE must address unmitigated risks associated with the use of agentic AI systems in healthcare.” Safety is critical for this project. The ISO does not require a specific formal method; propose the safety cases and formal methods that you think will best address safety.

Section 1.2.2 (TA3 description) states that TA3 performers will “have facilitated TA1 and TA2 agent integration and access to patient data from EHR and wearable /Remote Patient Monitoring (RPM) platforms.” 

Sharing as complete EHR data and wearable/RPM data as possible for the target population of patients with heart failure and/or post-myocardial infarction will help TA1 and TA2 performers be successful. 

However, TA2 is disease agnostic and therefore will benefit from a wider range of data. 

Section 1.2.1 (TA3 description) states that TA3 performers will “provide access to their EHR data and pre-production environments….” to the selected TA1 and TA2 performers. 

TA3’s goal in Phase 1B is to facilitate successful execution of TA1 and TA2 in their clinical and informatics environment. They could do so by providing access to their EHR pre-production environments to TA1 and TA2 performers in Phase 1Bsolutions and/or should explain how they will make that access and successful deployment possible and describe via their technical approaches (e.g., de-identification techniques, isolated “sandbox” environments, etc.).

Revenue sharing is not expected by the ADVOCATE program. T3 organizations are being paid to meet milestones that include sharing data, providing expertise, and collaborating with TA1 and TA2 performers for program success. Organizations may make their own agreements beyond the program.

TA2 proposals should have some clinical expertise in their team and a plan for clinical validation. TA2 performers will have multiple TA3 performers to provide data and clinical expertise.